ASTHMA

Relation between bronchial responsiveness to inhaled leukotriene D₄ and markers of leukotriene biosynthesis

P Gyllfors, M Kumlin, S-E Dahlén, F Gaber, P-O Ehre, B Dahlén

Thorax 2005;60:902–908. doi: 10.1136/thx.2005.041913

See end of article for authors' affiliations

Correspondence to:
Dr B Dahlén, Division of
Respiratory Medicine,
Department of Medicine,
Karolinska University
Hospital Huddinge,
SE-141 46 Stockholm,
Sweden; Barbro.dahlen@
medhs.ki.se

Received 4 February 2005
Accepted 13 July 2005
Published Online First
29 July 2005

Background: While clinical trials with antileukotrienes have shown overall beneficial effects in asthma, the factors that determine leukotriene dependent asthma are still unclear. A study was undertaken to determine whether or not leukotriene responsiveness in the airways correlates with endogenous leukotriene biosynthesis.

Methods: Bronchial responsiveness to leukotriene (LT) D₄ was assessed as PD₂₀FEV₁ in 20 subjects with mild asthma and 10 healthy controls, and compared with bronchial responsiveness to methacholine and two global measures of leukotriene production—urinary LTE₄ and ex vivo production of LTB₄ in whole blood.

Results: In patients with asthma the bronchoconstrictor activity of LTD₄ was about 1300 times greater than methacholine (geometric mean PD₂₀ 0.69 nmol v 887 nmol). Those who were most responsive to LTD₄ were relatively less responsive to methacholine ($p < 0.01$). There was, however, no correlation between bronchial responsiveness to LTD₄ and urinary LTE₄ or blood ex vivo LTB₄ levels in asthmatic subjects or healthy controls. Subjects with asthma treated with inhaled corticosteroids produced higher levels of LTB₄ ($p < 0.05$).

Conclusions: General measures of leukotriene production cannot predict bronchial responsiveness to LTD₄. The unique bronchoconstrictive potency of LTD₄ on human airways may relate to the locally regulated expression of the cysteinyl LT₁ receptor.

The leukotrienes (LT) and, in particular, the cysteinyl leukotrienes (CysLTs; LTC₄, LTD₄ and LTE₄) mediate central components of asthmatic airway inflammation such as bronchospasm, mucus production, eosinophil recruitment, and vascular reactions leading to tissue oedema.¹ Over the past decade antileukotrienes—that is, drugs which block the formation or actions of leukotrienes—have been introduced as new treatments for asthma. Antileukotrienes therefore have a completely different mode of action from that of other asthma medications.¹

The further clinical use of antileukotriene drugs is, however, hampered by a lack of understanding of which patients benefit from this treatment.¹ There is a distribution of clinical responsiveness to antileukotriene drugs that suggests the presence of responders and non-responders.^{2–5} Attempts to correlate the treatment response with genetic polymorphism in 5-lipoxygenase (the first enzyme in the leukotriene pathway) or leukotriene C₄ synthase (the enzyme initiating production of CysLTs) have produced conflicting results.^{6–8} So far, no major genetic determinant of leukotriene dependent asthma has been identified.

Another strategy in the quest to define responsiveness to antileukotriene drugs has been to define more precisely the phenotypic characteristics of such patients. The focus has been on the possibility that the propensity to generate leukotrienes during asthmatic inflammation is a marker of leukotriene dependent asthma. This hypothesis has received some support from the observations that subjects with aspirin intolerant asthma (AIA) respond well to antileukotriene treatment and have a high basal production of leukotrienes measured as urinary LTE₄ (U-LTE₄).^{9–11} It has also been claimed that the degree of ex vivo release of CysLTs from blood leucocytes is correlated directly with the clinical response to the leukotriene receptor antagonist pranlukast.¹²

However, in patients with AIA there was no correlation between U-LTE₄ and the treatment response to the leukotriene antagonist montelukast.⁵

While it is uncertain whether the production of leukotrienes correlates with the beneficial effect of antileukotrienes, the responsiveness to leukotrienes in the airways has not been taken into account. It is not known if increased bronchial responsiveness to leukotrienes is an indicator of a predominant leukotriene component in asthmatic inflammation. We have therefore embarked on a series of studies of factors that determine leukotriene responsiveness in the airways. The aim of the first investigation in this project was to assess whether or not the responsiveness of an individual to inhaled LTD₄ is related to the general propensity to synthesise leukotrienes. As CysLTs cause bronchoconstriction and many other biological effects by activation of the G protein coupled CysLT₁ receptor, it was hypothesised that there might be a relation between the endogenous level of agonist (CysLTs) and the airway responsiveness to inhaled LTD₄.¹³ It is common for agonist levels to influence the degree of receptor expression.¹⁴ For this study, two different global measures of leukotriene production—U-LTE₄ and blood ex vivo LTB₄ generation—were assessed. LTE₄ is the end product of the CysLTs excreted into the urine and its level is a reflection of whole body biosynthesis of CysLTs.¹⁵ As circulating levels of leukotrienes in the blood are very low and far below the detection limit of reliable assays, standardised ex vivo stimulation of whole blood with secretagogues such as a calcium ionophore has been

Abbreviations: CysLT, cysteinyl leukotriene; FEV₁, forced expiratory volume in 1 second; FeNO, fractional exhaled nitric oxide; ICS, inhaled corticosteroids; MCh, methacholine; PD₁₀, PD₁₅, PD₂₀, provocative dose causing a 10%, 15% and 20% decrease in FEV₁

introduced as an indirect method of assessing the biosynthetic capacity of blood cells for leukotriene production.¹⁶ In this setting LTB₄ is the main leukotriene formed, and its synthesis is thought to reflect the degree of 5-lipoxygenase activity.

This cross sectional study of 20 subjects with asthma and 10 healthy controls therefore tested whether bronchial responsiveness to LTD₄, expressed as the PD₂₀ value, was correlated with leukotriene production measured as U-LTE₄ and blood ex vivo production of LTB₄. Bronchial responsiveness to LTD₄ was also compared with responsiveness to methacholine (MCh), selected as a general marker of airway responsiveness, and with the fraction of expired nitric oxide (F_{ENO}) as a surrogate marker of airway inflammation, both being common asthma outcome variables in treatment studies. Although descriptive data on LTD₄ responsiveness are available in the literature, there is almost no mechanistic information about factors that determine leukotriene responsiveness in humans.¹⁷

METHODS

Subjects

Twenty subjects with intermittent to mild asthma according to GINA criteria¹⁸ and documented airway hyperresponsiveness to MCh and 10 healthy individuals were included in the study. Subjects with asthma were recruited from a general practitioner's clinic and the healthy volunteers through advertisements. All subjects were never smokers or non-smokers for the last 2 years with a smoking history of less than 5 pack years who had not had a respiratory tract infection during the 4 weeks before screening. Atopic subjects were not studied during seasonal allergen exposure and subjects with allergy to animal dander were required to avoid animal contact for >2 weeks before and during the study.

The 20 subjects with asthma were in a stable condition with forced expiratory volume in 1 second (FEV₁) ≥70% of predicted. Ten of the asthmatic subjects used a stable dose of inhaled corticosteroids (ICS) and short acting β₂ agonists as rescue, and 10 used short acting β₂ agonists as their sole medication (table 1).

The healthy individuals were skin prick test negative to 10 common allergen extracts and did not display significant bronchoconstriction with a fall of ≥20% in FEV₁ when challenged with a cumulative dose of 45 282 nmol MCh.

The study was approved by the ethical review board at the Karolinska University Hospital (EtDnr 00-267) and the subjects gave written informed consent before taking part.

Study design

The screening visit included subject characterisation with documentation of history, a MCh challenge, and a skin prick test. Three further visits were scheduled 2 weeks apart, and the subjects always reported to the clinic at the same time in the morning. At visit 1 F_{ENO} was measured according to the ATS/ERS standard,¹⁹ dynamic spirometric tests were performed, blood samples were collected for analysis of whole blood ex vivo LTB₄ production, and urinary samples were collected for analysis of baseline U-LTE₄ concentrations. In the subjects with asthma, quality of life was measured using the Asthma Quality of Life Questionnaire (AQLQ) devised by Juniper *et al.*²⁰ The patients were asked to indicate the extent to which their quality of life was limited on a 7-point scale where 1 indicates maximal impairment and 7 no impairment at all. At visit 2, blood and urine samples were collected and spirometric tests performed as the subjects underwent a bronchoscopic examination as part of a separate ongoing mechanistic investigation of the leukotriene pathway in the lung. At visit 3, inhalation challenge with LTD₄ was performed in addition to blood and urine sampling. Short acting β₂ agonists were withheld for at least 6 hours before visits except for visit 2.

Inhalation challenge

Pulmonary function was measured as FEV₁ on a spirometer (Vitalograph MDI Compact; Förbandsmaterial, Stockholm, Sweden) and the baseline defined as the best of three recordings. All bronchoprovocation tests were performed using a dosimeter controlled jet nebuliser (Spira Elektro 2; Intramedic, Bålsta, Sweden). Challenges always began with inhalation of the respective diluent. Provided FEV₁ did not change by more than 10%, incremental doses of the provocative agent were administered until FEV₁ had fallen by at least 20% from post-diluent baseline. For LTD₄ bronchoprovocation tests, approximately half-log increments in the cumulative dose (3, 10, 30 pmol) were inhaled every 10 minutes (dose range 3–335 780 pmol). This was achieved by using six solutions of good manufacturing practice (GMP) grade LTD₄ (sealed colour coded vials each containing 1 ml of solution; concentrations increasing by tenfold from 4.2×10⁻⁹ M to 4.2×10⁻³ M; 4:1 solvent water:ethanol; Cascade Biochemicals; Reading, UK) and a varying number of breaths (2–7) from each solution.⁹ Spirometric tests were performed 5 and 10 minutes after each dose and the peak fall used for calculation of PD₂₀. Airway responsiveness to MCh was assessed with a similar protocol but with dose increments every 3 minutes and single FEV₁ measurements.⁹

Table 1 Subject characteristics

	Healthy (n = 10)	Asthma (no ICS) (n = 10)	Asthma (ICS) (n = 10)
F/M	5/5	5/5	6/4
Mean (SD) age (years)	35 (10.1)	32 (8.6)	31 (6.9)
Mean (SD) FEV ₁ (l)	4.1 (0.7)	3.2 (0.6)	3.3 (1.0)
Mean (SD) FEV ₁ (% predicted)	110 (11.6)	90 (9.4)	91 (14.7)
Medication	–	SABA	Budesonide + SABA (n = 9; daily dose 400 µg n = 7, 800 µg n = 1, 1200 µg n = 1) Fluticasone propionate 500 µg + SABA (n = 1)
Mean (SD) SPT (out of 10)	–	3 (2.1)	3 (2.3)
Median (range) F _{ENO}	11.0 (6.3–19.7) n = 9	25.2 (6.8–198.6) n = 8	17.2 (6.1–86.5) n = 9
Mean (SD) asthma specific QoL	–	5.9 (0.88)	6.0 (0.73)

FEV₁, forced expiratory volume in 1 second; ICS, inhaled corticosteroid; SABA, short acting β agonist; SPT, skin prick test; F_{ENO}, fraction of exhaled nitric oxide; QoL, quality of life.
Lung function data at baseline (visit 1).

Figure 1 Individual dose-response curves for LTD₄ (left) and methacholine (right) in (A) healthy subjects, (B) non-ICS treated asthmatics, and (C) ICS treated asthmatic subjects. (D) Comparison of airway responsiveness to inhaled LTD₄ and methacholine indicated by the respective log PD₂₀ values in the asthmatic subjects ($r=0.73$, $p<0.001$, Pearson product moment correlation). ICS, inhaled corticosteroids.

Three concentrations (6.24, 50, 400 mM prepared at Norrlands University Hospital Pharmacy) were used to create increasing doses (range 89–45 282 nmol).

Collection of urine samples and analysis of urinary LTE₄

Urine was collected on arrival on each of the three study days, two samples at visit 1 with 1 hour in between and one sample at visits 2 and 3. The total volumes of the urine samples were measured, aliquoted, immediately frozen without preservatives, and stored at -20°C until analysis. The concentration of LTE₄ was determined using a previously validated enzyme immunoassay method with data expressed in relation to creatinine excretion determined colorimetrically.²¹ The rabbit polyclonal CysLT antiserum used in the present study cross reacted with LTE₄ (67%), LTC₄ (100%), and LTD₄ (100%). Acetylcholine esterase linked LTE₄ was used as tracer and unlabelled LTD₄ as standard. Baseline U-LTE₄ refers to the mean value of the four baseline samples.

Ex vivo ionophore induced formation of LTB₄ in whole blood

Blood samples were obtained by venepuncture into heparinised vacutainer tubes upon arrival at visits 1, 2 and 3. Ex vivo stimulation of freshly drawn peripheral whole blood was performed with a modified version of previously described protocols.^{16–22} The blood was kept at room temperature for 1 hour before incubation to minimise fluctuations in values due to decreased capacity for leukotriene formation within the first hour of blood collection.¹⁶ The calcium ionophore ionomycin was dissolved in 95% ethanol to a stock concentration of 10 mM. The stock solution and vehicle (95% ethanol) were diluted 10 times with autologous plasma. Aliquots of blood (1 ml) were preincubated at 37°C for 2 minutes, followed by addition of vehicle or ionomycin in

50 μl autologous plasma. The final concentration of ionomycin was 50 μM . Incubations were continued for 15 minutes at 37°C and interrupted on ice. Plasma was obtained by centrifugation at 714g for 5 minutes at 4°C and stored at -70°C until assayed for LTB₄ by enzyme immunoassay (Cayman Chemical, Ann Arbor, MI, USA). Data were expressed in relation to the white blood cell (WBC) count on each blood collection day. The mean values of the three visit days were used for comparisons between groups, whereas correlation with PD₂₀LTD₄ was tested for values obtained on the day of the bronchoprovocation (visit 3).

Statistical analysis

The provocative doses causing falls of 10%, 15% and 20% in FEV₁ (PD₁₀, PD₁₅, PD₂₀) were derived by linear interpolation from the respective log cumulated dose-response curves. Calculations of geometric mean values were performed on log transformed raw data. Urinary LTE₄ and ex vivo LTB₄ concentrations are expressed as median values with ranges. Correlations between bronchial challenges were performed with Pearson product moment correlation and all others with Spearman rank order correlation. The Mann-Whitney rank sum test was used for comparison between groups and Kruskal-Wallis one way analysis of variance on ranks was used to assess variability in values of ex vivo LTB₄ and U-LTE₄ at baseline. Differences were considered significant if $p<0.05$.

RESULTS

Bronchial responsiveness to LTD₄ and MCh

The dose-response relations for inhaled LTD₄ and MCh in all individuals are shown in fig 1A–C, and group mean data for different measures of responsiveness are given in table 2.

All subjects with asthma produced PD₂₀ values for LTD₄ and MCh with no significant difference in responsiveness between the group taking ICS and the group that did not

Table 2 Geometric mean (range) bronchial responsiveness data

	Healthy subjects (n = 10)	Asthma (no ICS) (n = 10)	Asthma (ICS) (n = 10)
PD ₂₀ LTD ₄ (nmol)	14.12 (6.47–40.37) (n = 7)	0.74 (0.06–6.43)	0.65 (0.15–37.05)
PD ₂₀ MCh (nmol)	nd	913 (89–25457)	862 (89–37188)
Ratio PD ₂₀ MCh/PD ₂₀ LTD ₄	nd	1234 (174–17557)	1326 (206–5825)
PD ₁₅ LTD ₄ (nmol)	16.50 (2.9–192.1) (n = 9)	0.41 (0.04–5.17)	0.41 (0.07–12.27)
Ratio PD ₁₅ LTD ₄ healthy v asthma	40.2 (16.5/0.41) (n = 29)		
PD ₁₅ MCh (nmol)	nd	659 (89–19316)	582 (89–27298)
Ratio PD ₁₅ MCh/PD ₁₅ LTD ₄	nd	1607 (575–30181)	1420 (240–5982)
PD ₁₀ LTD ₄ (nmol)	7.14 (1.14–54.24)	0.18 (0.01–1.25)	0.22 (0.04–5.00)
Ratio PD ₁₀ LTD ₄ healthy v asthma	35.7 (7.14/0.20) (n = 30)		
PD ₁₀ MCh (nmol)	12 974 (3830–47351) (n = 7)	330 (89–2430)	270 (89–9819)
Ratio PD ₁₀ MCh healthy v asthma	43.2 (12974/300) (n = 27)		
Ratio PD ₁₀ MCh/PD ₁₀ LTD ₄	1827 (321–7399) (n = 7)	1852 (832–18743)	1238 (116–4746)

MCh, methacholine; PD₁₀, PD₁₅, PD₂₀, provocative dose causing 10%, 15% and 20% decrease in FEV₁; nd, could not be determined.

(table 2). The geometric mean (range) PD₂₀LTD₄ and PD₂₀MCh for all subjects with asthma (n = 20) was 0.69 (0.062–37.05) nmol and 887 (89–37 188) nmol, respectively. Thus, on a molar basis, LTD₄ was over a 1000 times more potent than MCh (PD₂₀ ratio 877/0.69 = 1285; fig 1B and C). Very similar dose ratios between LTD₄ and MCh were also obtained if PD₁₅ or PD₁₀ values were compared in the subjects with asthma (table 2).

Airway responsiveness to LTD₄ was significantly correlated with responsiveness to MCh in the asthmatic subjects ($r = 0.73$, $p < 0.001$; fig 1D). However, across the range of airway hyperresponsiveness to MCh, LTD₄ was a relatively less potent bronchoconstrictor in the subjects with asthma most responsive to inhaled MCh and a more potent bronchoconstrictor in the subjects least responsive to inhaled MCh. There was a linear relation between airway responsiveness to MCh and the dose ratio of MCh to LTD₄ ($r = 0.6$, $p < 0.01$; fig 2).

In the healthy subjects the fall in FEV₁ in response to the highest cumulative dose of MCh (45 282 nmol) was less than 15% for eight of the 10 subjects (fig 1A). In contrast, LTD₄ produced a PD₂₀ in seven of the healthy subjects and PD₁₅ could be determined for nine (fig 1A and table 2). Compared with the asthmatic subjects, the healthy subjects were about

40 times less sensitive to either LTD₄ or MCh when PD₁₅ values for LTD₄ or PD₁₀ values for both compounds were compared (table 2). As in the asthmatic subjects, LTD₄ was more than 1000 times more potent than MCh when PD₁₀ values for LTD₄ and MCh were compared in the seven healthy individuals who responded to MCh (fig 1A and table 2).

There was no correlation between the responsiveness to inhaled LTD₄ and Feno in subjects with asthma or in healthy individuals at the PD₁₅ level (data not shown).

Blood ex vivo LTB₄ production and urinary excretion of LTE₄

Urinary LTE₄ excretion and ex vivo LTB₄ production were consistent within each study group with no significant differences between the three visit days (table 3), nor were there differences in baseline U-LTE₄ excretion between the three study groups ($p > 0.05$, table 3). However, asthmatic subjects taking ICS had higher ex vivo LTB₄ production than those with asthma not taking ICS (median (range) 10.7 (4.3–21.5) v 7.0 (2.5–18.1) ng/10⁶ WBC, $p < 0.05$). There was no correlation between ex vivo LTB₄ production and U-LTE₄ in either the asthmatic subjects ($p > 0.05$) or in the healthy individuals ($p > 0.05$, data not shown).

Furthermore, there was no correlation between airway responsiveness to LTD₄ and ex vivo LTB₄ generation on the day of provocation in subjects with asthma (n = 20, $r = 0.36$, $p = 0.12$) or in the healthy individuals (n = 7, $r = -0.12$, $p = 0.80$; fig 3A). Likewise, there was no correlation between responsiveness to inhaled LTD₄ and baseline U-LTE₄ concentrations in subjects with asthma (n = 20, $r = -0.22$, $p = 0.36$) or in healthy individuals (n = 7, $r = -0.17$, $p = 0.71$; fig 3B).

DISCUSSION

No relationship was found between two global measures of leukotriene biosynthesis and bronchial responsiveness to inhaled LTD₄. Although baseline data (including asthma specific quality of life) indicated that the subjects with asthma had relatively similar disease severity, their responsiveness to LTD₄ varied by almost 1000 times (PD₂₀ from 60 pmol to 40 nmol (30 ng to 20 µg)). There was also no relation between LTD₄PD₂₀ and exhaled NO, although the latter displayed the expected difference between healthy subjects and asthmatics (table 1).

Figure 2 Relation between airway responsiveness to methacholine (PD₂₀) and the relative potency of LTD₄ compared with methacholine (dose ratio of MChPD₂₀ to LTD₄PD₂₀). The linear relation between the two variables ($r = 0.6$, $p < 0.01$, Pearson product moment correlation) indicates that the asthmatic subjects who were the most responsive to methacholine had the least relative airway responsiveness to LTD₄.

Table 3 Median (range) leukotriene levels on the three visit days

	Visit 1	Visit 2	Visit 3
Blood ex vivo LTB ₄ (ng/10 ⁶ WBC)			
Healthy subjects	9.14 (4.09–18.46)	9.19 (4.65–24.78)	10.38 (3.66–24.92)
Asthma, not ICS	6.32 (3.31–13.56)	8.02 (2.47–18.14)	9.47 (5.26–17.97)
Asthma ICS	8.04 (4.34–21.55)	10.55 (7.43–21.20)	11.80 (6.45–16.54)
Baseline urinary LTE ₄ (ng/mmol creatinine)			
Healthy subjects	22.64 (16.34–48.15)	23.78 (14.44–46.30)	20.29 (14.16–36.23)
Asthma, not ICS	24.41 (16.85–51.96)	20.30 (15.38–56.13)	28.63 (13.50–43.81)
Asthma ICS	22.92 (11.69–59.35)	20.92 (11.90–55.00)	21.73 (11.64–57.76)

WBC, white blood cells; ICS, inhaled corticosteroids.

Within each study group there was no significant difference between the three study days (ANOVA) for any of the variables.

In the search for factors that determine leukotriene responsiveness in the airways, the effects of inhaled LTD₄ were examined in one of the largest bronchoprovocation studies (n = 30) completed with this agent. Subjects with mild asthma, half of whom were receiving treatment with ICS, were chosen because they represent the vast majority (approximately 70%) of all asthma patients. Thus, in subjects with asthma, LTD₄ was (on a molar basis) more than 1000 times (1285) more potent than MCh (geometric mean PD₂₀ values obtained after inhalation: 650 pmol LTD₄ (325 ng) v >900 nmol MCh (270 µg)). This potency ratio compares well with other bronchoprovocation studies and with investigations in isolated human airways.^{17–23} In the asthmatic subjects there was, however, no difference in absolute or relative responsiveness to LTD₄ or MCh between subjects on ICS and those not on ICS.

On the other hand, the asthmatic subjects who were the most responsive to MCh had the lowest relative airway responsiveness to LTD₄ compared with MCh. The relation between responsiveness to LTD₄ and standard direct bronchoconstrictors has been debated.^{24–26} The relationship we found between responsiveness to MCh and LTD₄ supports previous findings.^{27–28} Ådelroth *et al* hypothesised that asthmatic subjects with more severe airway inflammation and greater MCh responsiveness somehow had developed a specific tachyphylaxis to inhaled CysLTs, possibly as a result of increased local biosynthesis of CysLTs. Interestingly, Ketchell *et al* found that bronchial responsiveness to MCh but not to LTD₄ was increased after allergen challenge, findings that indirectly are in line with Ådelroth's hypothesis and our findings.²⁹ Thus, although MCh and LTD₄ are both direct bronchoconstrictors, the difference in relative potency for the two classes of bronchoconstrictors in asthmatics with varying degree of hyperresponsiveness indicates that each

bronchoconstrictor has unique effects on the airways in asthma. Our findings support the hypothesis²⁷ that subjects with asthma and a high degree of airway reactivity have developed tachyphylaxis to LTD₄, presumably because of high exposure to endogenous LTD₄ in their inflamed airways. Another explanation for the findings in fig 2 might be that LTD₄ in subjects with more inflamed airways stimulates the release of bronchoprotective factors such as nitric oxide or prostaglandin E₂. The conclusion that LTD₄ has a very specific mode of action on the airways is also supported by the current observation that there was no relation between LTD₄PD₂₀ and exhaled NO, whereas MCh responsiveness has been reported to be correlated with exhaled NO levels.³⁰

It was confirmed that LTD₄ is also a potent bronchoconstrictor in subjects without asthma.^{24–26} Interestingly, a PD₂₀ value for LTD₄ could be obtained in seven out of 10 healthy individuals whereas only two subjects had a fall in FEV₁ of more than 12% after inhalation of the highest dose of MCh used in this protocol. The latter observation is in line with the established plateau to MCh in healthy subjects.³¹ The less apparent plateau to LTD₄ might relate to its longer duration of action in airway smooth muscle compared with agonists such as histamine or MCh.²³ Bel *et al* found that the maximal airway narrowing to LTD₄ was much greater than that produced by MCh.³² In agreement with these fundamental differences in action on the airways, the potency ratio between LTD₄ and MCh (1827) could only be determined on a PD₁₀ level in the healthy controls. However, when LTD₄ responsiveness was compared for the groups, the healthy controls were about 40 times less responsive than the subjects with asthma.

Baseline urinary excretion of LTE₄ was the same in all three groups studied, and there was no relation between baseline U-LTE₄ and PD₂₀ for inhaled LTD₄ in subjects with

Figure 3 No relation was seen between airway responsiveness to inhaled LTD₄ and two general markers of leukotriene production in subjects with asthma or in healthy individuals (Spearman rank order correlation): (A) blood ex vivo LTB₄ production; (B) baseline U-LTE₄ concentration.

asthma and healthy controls. Measurements of ex vivo LTB₄ formation in whole blood also failed to establish a relation between this measure and airway responsiveness to LTD₄ for asthmatics or healthy controls. Taken together, the study therefore refuted the hypothesis that there is a relation between airway responsiveness to LTD₄ and the global propensity of individuals to generate leukotrienes measured either as U-LTE₄ or blood ex vivo LTB₄ production. It is likely that the expression of CysLT₁ receptors in the airways is the primary determinant of responsiveness to inhaled LTD₄. CysLT₁ receptor expression and hence airway responsiveness to the inhaled agonist may, however, still be regulated by the local biosynthesis of leukotrienes in the airways measured, for example, in sputum, bronchoalveolar lavage (BAL) fluid or cells recovered from BAL fluid. Mechanistic studies to address these possibilities are ongoing.

Interestingly, we found that asthmatic patients who were receiving ICS produced somewhat higher levels of LTB₄, whereas their urinary excretion of LTE₄ was the same as in asthmatic patients not treated with ICS. The finding with LTB₄ is new and, together with the confirmatory data on urinary LTE₄, adds to the knowledge that ICS have complex effects on the leukotriene pathway with no or minimal effects on leukotriene biosynthesis generally observed in vivo.^{33–35} The increased levels of steroid treatment might relate to the previous finding that 5-lipoxygenase and FLAP expression in cells may be upregulated by ICS.³⁶ As there was no correlation between ex vivo generation of LTB₄ and U-LTE₄ for the individual subjects, the study also confirms the hypothesis that these two measures represent two different ways to assess the leukotriene pathway.

In conclusion, the lack of relationship between global markers of biosynthesis of leukotrienes and responsiveness to LTD₄ is noteworthy in view of the limited usefulness of these markers to predict the response to antileukotriene drugs. Since subjects with asthma in the current study displayed a wide three log order of magnitude variability in responsiveness to inhaled LTD₄, variability in the sensitivity of the target tissue to the effects of CysLTs may perhaps be a more decisive determinant of the treatment response to antileukotriene drugs. We therefore propose that future trials aimed at the establishment of responders to antileukotriene treatment should include PD₂₀FEV₁ for LTD₄. We hypothesise that such a direct measure of airway responsiveness may be more predictive than the markers of biosynthesis currently investigated. Alternatively, a composite measurement integrating both airway responsiveness and an appropriate end point for leukotriene biosynthesis may be required to define leukotriene dependent asthma.

ACKNOWLEDGEMENTS

The authors acknowledge the assistance from Ingrid Delin, Margaretha Andersson, Margitha Dahl, Gunnel de Forest, Heléne Blomqvist, and Elisabeth Henriksson.

Authors' affiliations

P Gyllfors, Division of Respiratory Medicine, Department of Medicine at Karolinska University Hospital Solna, Centre for Allergy Research at Karolinska Institutet, Stockholm, Sweden

M Kumlin, **S-E Dahlén**, **F Gaber**, **P-O Ehlers**, Division of Physiology, The National Institute of Environmental Medicine, Centre for Allergy Research at Karolinska Institutet, Stockholm, Sweden

P-O Ehlers, Family Medicine Stockholm, Department of Clinical Science, Centre for Allergy Research at Karolinska Institutet, Stockholm, Sweden

B Dahlén, Division of Respiratory Medicine, Department of Medicine at Karolinska University Hospital Huddinge, Centre for Allergy Research at Karolinska Institutet, Stockholm, Sweden

Supported by Karolinska Institutet, Centre for Allergy Research and the Stockholm County Council (ALF), and the following Swedish foundations: Heart Lung Foundation, Association Against Asthma and Allergy, Consul

Bergh's Foundation, Medical Research Council (projects 14X-9071 and 74X-15067), and the Foundation for Health Care Sciences and Allergy Research (Vårdal). This study received no support from the pharmaceutical industry.

Competing interests: none declared

REFERENCES

- 1 **Drazen JM**, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. *N Engl J Med* 1999;**340**:197–206.
- 2 **Fish JE**, Kemp JP, Lockey RF, *et al*. Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group. *Clin Ther* 1997;**19**:675–90.
- 3 **Israel E**, Cohn J, Dube L, *et al*. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. *JAMA* 1996;**275**:931–6.
- 4 **Malmstrom K**, Rodriguez-Gomez G, Guerra J, *et al*. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. *Ann Intern Med* 1999;**130**:487–95.
- 5 **Dahlen SE**, Malmstrom K, Nizankowska E, *et al*. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. *Am J Respir Crit Care Med* 2002;**165**:9–14.
- 6 **Drazen JM**, Yandava CN, Dube L, *et al*. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. *Nat Genet* 1999;**22**:168–70.
- 7 **Sampson AP**, Siddiqui S, Buchanan D, *et al*. Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. *Thorax* 2000;**55**(Suppl II):S28–31.
- 8 **Currie GP**, Lima JJ, Sylvester JE, *et al*. Leukotriene C4 synthase polymorphisms and responsiveness to leukotriene antagonists in asthma. *Br J Clin Pharmacol* 2003;**56**:422–6.
- 9 **Dahlen B**, Nizankowska E, Szczeklik A, *et al*. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. *Am J Respir Crit Care Med* 1998;**157**:1187–94.
- 10 **Christie PE**, Tagari P, Ford-Hutchinson AW, *et al*. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. *Am Rev Respir Dis* 1991;**143**:1025–9.
- 11 **Kumlin M**, Dahlen B, Björck T, *et al*. Urinary excretion of leukotriene E4 and 11-dehydro-thromboxane B2 in response to bronchial provocations with allergen, aspirin, leukotriene D4, and histamine in asthmatics. *Am Rev Respir Dis* 1992;**146**:96–103.
- 12 **Terashima T**, Amakawa K, Matsumaru A, *et al*. Correlation between cysteinyl leukotriene release from leukocytes and clinical response to a leukotriene inhibitor. *Chest* 2002;**122**:1566–70.
- 13 **Brink C**, Dahlén SE, Drazen JM, *et al*. International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors. *Pharmacol Rev* 2003;**55**:195–227.
- 14 **Small KM**, McGraw DW, Liggett SB. Pharmacology and physiology of human adrenergic receptor polymorphisms. *Ann Rev Pharmacol Toxicol* 2003;**43**:381–411.
- 15 **Sala A**, Voelkel N, Maclof J, *et al*. Leukotriene E₄ elimination and metabolism in normal human subjects. *J Biol Chem* 1990;**265**:21771–8.
- 16 **Surette ME**, Odeimat A, Palmantier R, *et al*. Reverse-phase high-performance liquid chromatography analysis of arachidonic acid metabolites in plasma after stimulation of whole blood ex vivo. *Anal Biochem* 1994;**216**:392–400.
- 17 **Drazen JM**. Effects of cysteinyl leukotrienes on human airways. In: Holgate S, Dahlén SE, eds. *SRS-A to leukotrienes: the dawning of a new treatment*. UK: Blackwell Science, 1997:189–201.
- 18 **Anon**. *Global strategy for asthma management and prevention*, NIH publication no 02-3659, 2002. Available at www.ginaasthma.com.
- 19 **Kharitonov S**, Alving K, Barnes PJ. Exhaled and nasal nitric oxide measurements recommendations. The European Respiratory Society Task Force. *Eur Respir J* 1997;**10**:1683–93.
- 20 **Juniper EF**, Guyatt GH, Ferrie PJ, *et al*. Measuring quality of life in asthma. *Am Rev Respir Dis* 1993;**147**:832–8.
- 21 **Kumlin M**, Stensvad F, Larsson L, *et al*. Validation and application of a new simple strategy for measurements of urinary leukotriene E4 in humans. *Clin Exp Allergy* 1995;**25**:467–79.
- 22 **Brideau C**, Chan C, Charleson S, *et al*. Pharmacology of MK-0591 [3-[1-(4-chlorobenzyl)-3-(1-butylthio)-5-(quinolin-2-yl-methoxy)-2,2-dimethyl propanoic acid], a potent, orally active leukotriene biosynthesis inhibitor. *Can J Physiol Pharmacol* 1992;**70**:799–807.
- 23 **Dahlen SE**, Hedqvist P, Hammarstrom S, *et al*. Leukotrienes are potent constrictors of human bronchi. *Nature* 1980;**288**:484–6.
- 24 **Smith LJ**, Greenberger PA, Patterson R, *et al*. The effect of inhaled leukotriene D4 in humans. *Am Rev Respir Dis* 1985;**131**:368–72.
- 25 **Weiss JW**, Drazen JM, McFadden ER Jr, *et al*. Airway constriction in normal humans produced by inhalation of leukotriene D₄. Potency, time course, and effect of aspirin therapy. *JAMA* 1983;**249**:2814–7.
- 26 **Barnes NC**, Piper PJ, Costello JF. Comparative effects of inhaled leukotriene C4, leukotriene D4, and histamine in normal human subjects. *Thorax* 1984;**39**:500–4.
- 27 **Adelroth E**, Morris MM, Hargreave FE, *et al*. Airway responsiveness to leukotrienes C4 and D4 and to methacholine in patients with asthma and normal controls. *N Engl J Med* 1986;**315**:480–4.
- 28 **Griffin M**, Weiss JW, Leitch AG, *et al*. Effects of leukotriene D on the airways in asthma. *N Engl J Med* 1983;**308**:436–9.

- 29 Ketchell RI, D'Amato M, Jensen MW, *et al*. Contrasting effects of allergen challenge on airway responsiveness to cysteinyl leukotriene D₄ and methacholine in mild asthma. *Thorax* 2002;**57**:575–80.
- 30 Jatakanon A, Lim S, Kharitonov SA, *et al*. Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma. *Thorax* 1998;**53**:91–5.
- 31 Sterk PJ, Timmers MC, Dijkman JH. Maximal airway narrowing in humans in vivo. Histamine compared with methacholine. *Am Rev Respir Dis* 1986;**134**:714–8.
- 32 Bel EH, van der Veen H, Kramps JA, *et al*. Maximal airway narrowing to inhaled leukotriene D₄ in normal subjects. Comparison and interaction with methacholine. *Am Rev Respir Dis* 1987;**136**:979–84.
- 33 Manso G, Baker AJ, Taylor IK, *et al*. In vivo and in vitro effects of glucocorticosteroids on arachidonic acid metabolism and monocyte function in nonasthmatic humans. *Eur Respir J* 1992;**5**:712–6.
- 34 Dworski R, Fitzgerald GA, Oates JA, *et al*. Effect of oral prednisone on airway inflammatory mediators in atopic asthma. *Am J Respir Crit Care Med* 1994;**149**:953–9.
- 35 O'Shaughnessy KM, Wellings R, Gillies B, *et al*. Differential effects of fluticasone propionate on allergen-evoked bronchoconstriction and increased urinary leukotriene E₄ excretion. *Am Rev Respir Dis* 1993;**147**:1472–6.
- 36 Riddick CA, Ring WL, Baker JR, *et al*. Dexamethasone increases expression of 5-lipoxygenase and its activating protein in human monocytes and THP-1 cells. *Eur J Biochem* 1997;**246**:112–8.

LUNG ALERT

Roflumilast as a treatment for COPD

▲ Rabe KF, Bateman ED, O'Donnell D, *et al*. Roflumilast—an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. *Lancet* 2005;**366**:563–71

Chronic inflammation is the key pathophysiological mechanism in the development of COPD and there is increasing interest in the potential role of novel anti-inflammatory treatments. This phase III multicentre double blind study focuses on roflumilast, an oral phosphodiesterase 4 inhibitor.

1411 patients with stable moderate to severe COPD were randomised to receive placebo, roflumilast 250 µg once daily, or roflumilast 500 µg once daily for 24 weeks. The primary outcome measures were post-bronchodilator forced expiratory volume in 1 second (FEV₁) and St George's Respiratory Questionnaire (SGRQ) total score. Secondary outcome measures included the number of COPD exacerbations. The results showed a mean (SD) improvement in FEV₁ of 74 (18) ml with roflumilast 250 µg and 97 (18) ml with roflumilast 500 µg compared with placebo at 24 weeks ($p < 0.0001$). There were no significant differences in the SGRQ scores between the roflumilast and placebo groups. The mean number of exacerbations was reduced by 34% in the roflumilast 500 µg group compared with the placebo group, primarily due to a reduction in mild exacerbations (42%, $p = 0.004$). Adverse effects were predominantly gastrointestinal in nature and self-limiting.

This study provides encouraging initial data to support the use of roflumilast in patients with COPD. Further studies are needed to confirm that these results are sustained beyond 24 weeks and to assess further the effects on health-related quality of life.

E Nash

Specialist Registrar, Frenchay Hospital, Bristol, UK; ednash2000@hotmail.com